



The Illinois Medical Bulletin



The Role of the BCR-ABL Fusion Gene in the Pathogenesis of Chronic Myeloid Leukemia: A Review of the Foundational Molecular and Clinical Evidence

¹A. Braden, ²A. Breitenbach

^{1,2} University of Illinois College of Medicine

Corresponding Email : bradenmd298474@gmail.com

Article History :

Received date : 2015/10/12
Revised date : 2015/11/28
Accepted date : 2015/12/09
Published date : 2016/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Chronic Myeloid Leukemia (CML), a once fatal myeloproliferative neoplasm, became the archetype of successful molecularly targeted therapy in oncology. This transformation was entirely dependent on the identification of a single, causative genetic abnormality. This review synthesises the foundational literature published before 2010 that established the causal role of the *BCR-ABL* fusion gene in the pathogenesis of CML and chronicled the development of therapy directed against it.

Literature Review: The scientific narrative began with the discovery of a consistent cytogenetic marker, the Philadelphia chromosome, which was later identified as a reciprocal translocation between chromosomes 9 and 22. Research in the 1980s pinpointed the molecular consequence: the creation of the *BCR-ABL* fusion gene. This oncogene was proven to encode a constitutively active tyrosine kinase protein, which drives the uncontrolled proliferation and anti-apoptotic signaling that define CML. This precise molecular understanding spurred the

rational design of Imatinib mesylate, a specific BCR-ABL kinase inhibitor. Landmark clinical trials in the early 2000s demonstrated that Imatinib produced unprecedented rates of complete and durable remissions, transforming the disease's natural history.

Conclusion: The pre-2010 literature provides a complete and triumphant arc from a descriptive cytogenetic discovery to a life-saving molecular therapy. It confirms that the *BCR-ABL* oncogene is the necessary and sufficient driver of CML, and that its targeted inhibition represents one of the most successful applications of molecular medicine in history.

Keywords: Chronic Myeloid Leukemia (CML), BCR-ABL, Philadelphia Chromosome, Imatinib, Targeted Therapy.

INTRODUCTION

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder characterized by the excessive production of mature and maturing granulocytes. For most of the 20th century, it was a uniformly fatal disease, with a median survival of only three to five years, and treatments such as chemotherapy and interferon offered only modest benefits. The story of CML, however, evolved into a landmark of modern medicine, representing the single most successful example of translating a basic molecular discovery into a highly effective, life-altering therapy.

This revolution was predicated on the discovery of a single, consistent genetic abnormality that was found to be the underlying driver of the disease. This began with the identification of a unique chromosomal marker, the Philadelphia chromosome, and culminated in the development of a drug designed specifically to inhibit the protein encoded by its resultant fusion gene, *BCR-ABL*. This literature review aims to examine the foundational body of scientific work published before 2010 that established the definitive causal link between the *BCR-ABL* oncogene and the pathogenesis of CML, and chronicled the clinical triumph of its targeted inhibition.

LITERATURE REVIEW

The understanding of CML's pathogenesis is a chronological story of scientific discovery, beginning at the chromosomal level and progressively focusing on a single molecular target.

The journey began in 1960 with the discovery by Nowell and Hungerford of an abnormally small chromosome, later named the Philadelphia (Ph) chromosome, which was consistently

present in the leukemic cells of patients with CML. For over a decade, its origin was a mystery. The breakthrough came in 1973, when Janet Rowley, using new chromosome banding techniques, demonstrated that the Ph chromosome was not a simple deletion but the result of a reciprocal translocation between the long arms of chromosomes 9 and 22, denoted as t(9;22)(q34;q11) (Rowley, 1973). This finding proved that cancer could be caused by a specific, acquired genetic rearrangement.

The next crucial step was to identify the molecular consequence of this translocation. In the mid-1980s, research groups successfully cloned the breakpoint on chromosome 22, which occurred within a gene named the "breakpoint cluster region" (BCR), and found that it fused with the Abelson murine leukemia viral oncogene homolog 1 (ABL1), a proto-oncogene from chromosome 9. This created a novel hybrid gene, *BCR-ABL* (Deininger et al., 2000). The ABL1 protein is a tightly regulated tyrosine kinase, a type of enzyme that functions as a cellular "on-off" switch for many processes. The fusion with BCR results in the production of a BCR-ABL protein in which the ABL kinase domain is permanently "switched on." This constitutively active kinase was shown to activate a cascade of downstream signaling pathways that promote cell division, inhibit programmed cell death (apoptosis), and alter cell adhesion, thereby conferring all the necessary characteristics for leukemic transformation (Deininger et al., 2000).

The identification of a single, causative enzyme that was unique to the cancer cells provided a perfect target for drug development. This spurred a campaign of rational drug design to find a small molecule that could specifically block the function of the BCR-ABL kinase. This effort culminated in the development of STI571, later known as Imatinib mesylate. This molecule was designed to fit precisely into the ATP-binding pocket of the BCR-ABL kinase, preventing it from functioning and thereby shutting down the downstream signaling that drives the leukemia. The clinical results were stunning. The phase I trial, published by Druker et al. (2001), showed that Imatinib produced complete hematologic responses in nearly all chronic-phase CML patients who had failed prior therapy. This was swiftly followed by the international randomized IRIS trial, which compared Imatinib to the then-standard-of-care (interferon-alfa plus cytarabine) as first-line therapy. The results, published by O'Brien et al. (2003), were so overwhelmingly in favour of Imatinib, with unprecedented rates of durable cytogenetic and hematologic remission and far superior tolerability, that it immediately became the new global standard of care.

CONCLUSION

The literature published before 2010 on the relationship between the *BCR-ABL* gene and Chronic Myeloid Leukemia tells a complete and paradigm-shifting story. It begins with the landmark discovery of the Philadelphia chromosome and progresses to the identification of the *BCR-ABL* fusion gene as the specific and singular molecular driver of the disease. The understanding of its function as a constitutively active tyrosine kinase provided the precise target needed for rational drug design.

The subsequent development and spectacular clinical success of the BCR-ABL inhibitor, Imatinib, validated the entire scientific hypothesis. It proved that CML is dependent on the activity of this single oncoprotein and demonstrated that its targeted inhibition could effectively control the disease. This body of work not only transformed CML from a fatal leukemia into a manageable chronic condition for the vast majority of patients but also provided the definitive proof-of-concept for targeted cancer therapy, ushering in a new era of molecularly-informed oncology.

REFERENCES

- Deininger, M.W., Goldman, J.M. and Melo, J.V. (2000) 'The molecular biology of chronic myeloid leukemia', *Blood*, 96(10), pp. 3343-3356.
- Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C.L. (2001) 'Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia', *New England Journal of Medicine*, 344(14), pp. 1031-1037.
- Nowell, P.C. and Hungerford, D.A. (1960) 'A minute chromosome in human chronic granulocytic leukemia', *Science*, 132(3438), p. 1497.
- O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J.L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J.M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A.E., Capdeville, R. and Druker, B.J. (2003) 'Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia', *New England Journal of Medicine*, 348(11), pp. 994-1004.

Rowley, J.D. (1973) 'Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining', *Nature*, 243(5405), pp. 290-293.